OpGen, Curetis, and Ares Genetics have combined their businesses to build stronger diagnostic solutions for severe infections. Read more.
Optimizing Genomic Testing for Antibiotic Resistance
Existing tests can take days to identify the correct treatment for a patient’s infection. That’s why caregivers often use broad-spectrum antibiotics as a first defense—but when those drugs are overused, antibiotic-resistant microbes can emerge. OpGen is developing a better way to treat infection while preventing antibiotic resistance. We harness the power of informatics and genomics to identify antimicrobial resistant (AMR) organisms quickly and accurately, with an aim to improve treatment at the patient, hospital, and network level.
Deaths each year from bacterial infections (WHO)
Deaths annually in the us & europe from drug-resistant infections
Excess direct healthcare costs in the us from drug-resistant infections
OpGen Subsidiary Curetis GmbH Secures Access to Additional EUR 5.0 Million Non-Dilutive Debt Financing Tranche from EIB MORE
OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours MORE
OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections MORE
There are currently no upcoming events.
Latest Blog Posts
Evaluation of a Multiplex Molecular Assay for the Detection of Respiratory Pathogens from Tracheal Aspirates and Sputa MORE
A comparison of two molecular panels for culture independent detection of lower respiratory tract pathogens MORE
Analytical and Clinical Evaluation of the Curetis Unyvero Lower Respiratory Panel at a Tertiary Care Cancer Center MORE